Skip to main content
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Subscribe
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Ofer M. Wellisch, MD, MPH
Authored Items
Personalized Medicine for Patients with Chronic Pain
Ofer M. Wellisch, MD, MPH
Faculty Perspectives in Chronic Pain:Utilizing Pharmacogenomics When Selecting Personalized Medicine for Patients with Chronic Pain
Abuse-Deterrent Formulations: An Early Epidemiologic Appraisal
Ofer M. Wellisch, MD, MPH
Faculty Perspectives in Chronic Pain: Epidemiologic Assessments of Abuse-Deterrent Formulations
Clinical Assessment of Abuse-Deterrent Formulations
Ofer M. Wellisch, MD, MPH
Faculty Perspectives in Chronic Pain: In Vitro and Clinical Assessments of Abuse-Deterrent Formulations for Chronic Pain
Last modified: January 5, 2016